+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Gynecology Drugs Global Market Report 2024

  • PDF Icon

    Report

  • 200 Pages
  • February 2024
  • Region: Global
  • The Business Research Company
  • ID: 5939271
The gynecology drugs market size has grown strongly in recent years. It will grow from $41.56 billion in 2023 to $43.78 billion in 2024 at a compound annual growth rate (CAGR) of 5.4%. The expansion observed in the historical period can be attributed to several factors, including the introduction of drugs with novel mechanisms, increased availability of educational tools and awareness regarding menopause, a rise in the use of long-acting reversible contraceptives, shifts in lifestyles, heightened healthcare awareness and expenditure, government initiatives, and an increase in pharmaceutical research and development (R&D) expenditure.

The gynecology drugs market size is expected to see strong growth in the next few years. It will grow to $54.1 billion in 2028 at a compound annual growth rate (CAGR) of 5.4%. The forecasted growth is driven by increased awareness and use of contraceptives and hormone replacement therapy (HRT), a rise in age-related gynecological cancers, higher ovarian cancer cases, prevalence of gynecological diseases, increased healthcare expenditure, and investments in understanding endometriosis mechanisms. Key trends include launching new treatments for oncology and endometriosis, developing menopausal hormone therapies, research investments in gynecology drugs, awareness efforts on contraceptive benefits, product launches for unmet needs, antibody-drug conjugates for ovarian cancers, strategic collaborations for portfolio expansion, and focus on combination therapies to address drug resistance in cancer treatments.

The anticipated increase in the number of women affected by ovarian cancer is expected to drive growth in the global gynecological drugs market. Ovarian cancer, originating in the ovaries as part of the female reproductive system, is effectively managed by gynecological drugs that offer targeted treatment options, improved survival rates, and enhanced quality of life for patients. According to estimates from Globocan, the global incidence of ovarian cancer is projected to reach 434,184 by 2040, thereby fostering the demand for gynecological drugs in the foreseeable future.

Age serves as a significant risk factor for various diseases, including diabetes, obesity, neurodegenerative disorders, and cancer. In particular, disruptions in female reproductive cycles, such as early menarche or late menopause, contribute to hormonal imbalances and increase the risk of cancer in later stages of life. Endometrial and ovarian cancers are prevalent among elderly women and contribute to substantial mortality rates. The incidence of these cancers rises with age, typically peaking around 60 to 70 years. Additionally, cervical cancer is commonly diagnosed around the age of 50, while vaginal and vulvar cancers are typically diagnosed later, around the age of 67. For instance, the American Cancer Society estimates 14,000 new cases of cervical cancer in the United States in 2022. The age-related upswing in gynecological cancers is expected to propel the market in the coming years.

There is a noteworthy trend in the pharmaceutical industry where companies are investing in the development of personalized cancer vaccines, including those for gynecological cancers. Some of these vaccines have progressed to clinical trial phases, demonstrating the industry's commitment to leveraging genetic sequencing and precision medicine for patient-specific drug therapies. Notably, Moderna reported positive results from an ongoing Phase 1 clinical study of its mRNA-4157 personalized cancer vaccine, designed for patients with both resected and unresected solid tumors. The vaccine is currently in Phase 2 clinical trials.

The introduction of gynecological drug treatments by major companies represents a positive trend in the market. Given the competitive landscape and the presence of multiple players, companies are focusing on advanced drug development to introduce new and effective treatments. For example, in September 2021, Myovant Sciences, a UK-based biopharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) had accepted a supplemental New Drug Application (sNDA) for MYFEMBREE, a drug designed to manage moderate to severe pain associated with endometriosis. The FDA set a target action date of May 6, 2022, for the sNDA under the Prescription Drug User Fee Act (PDUFA).

In March 2022, Carlyle, a U.S.-based private equity firm, and PAI Partners, a France-based private equity firm, reached an agreement to acquire Theramex from CVC Capital Partners for $1.4 billion. This acquisition is intended to expand the investment portfolio of Carlyle and PAI in Theramex, focusing on organic, inorganic, and international growth initiatives. Theramex, a UK-based pharmaceutical company, specializes in women's health products related to fertility, contraception, menopause, and osteoporosis.

Major companies operating in the gynecology drugs market report are Merck & Co. Inc., AbbVie, Hoffmann-La Roche Ltd., GlaxoSmithKline PLC, Pfizer Inc., Furukawa Electric, Motherson Sumi, LS Cables & Systems, HUBER+SUHNER., Acome, Yazaki Corporation, Fujikura Ltd., Robert Bosch, HELLA GmbH & Co. KGaA, Coroplast Harness Technology Sp. z oo sp. k, EK Elektrokabel FABRYKA KABLI Karolak i synowie sp. z o.o., Coroflex Poland Sp. z o.o Sp. k., Eltrim Kable Sp. z o. o, Anixter, Allied Wire & Cable Inc., Emcocables, Navcar S.A.S, Wirex Cable SA, Sistemas de Argentina S.A, ARJ Water Technology LLC, Fajr Al Hind LLC, Haji Commercial Co LLC, Bahra Cables, Coficab Group.

North America was the largest region in the gynecology drugs market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the gynecology drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the gynecology drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.

The primary therapeutic categories within gynecology drugs include hormonal therapy and non-hormonal therapy. Hormonal therapy involves treatments that either add, block, or remove hormones to impede the growth of cancer cells reliant on hormones for their development. Non-hormonal therapy includes the use of anti-infective and anti-inflammatory agents, lubricants, moisturizers, as well as medications such as antidepressants, gabapentin, clonidine, among others. Gynecology drugs find application in treating conditions such as gynecological cancers, menopausal disorders, polycystic ovary syndrome, contraception, and more. These drugs are distributed through various channels, including hospital pharmacies, retail pharmacies, and online pharmacies.

The gynecology drugs market research report is one of a series of new reports that provides gynecology drugs market statistics, including gynecology drugs industry global market size, regional shares, competitors with a gynecology drugs market share, detailed gynecology drugs market segments, market trends and opportunities, and any further data you may need to thrive in the gynecology drugs industry. This gynecology drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The gynecology market consists of sales of belantamab, relugolix, selumitinib, and avapritinib. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.

Table of Contents

1. Executive Summary2. Gynecology Drugs Market Characteristics3. Gynecology Drugs Market Trends and Strategies
4. Gynecology Drugs Market - Macro Economic Scenario
4.1. Impact of High Inflation on the Market
4.2. Ukraine-Russia War Impact on the Market
4.3. COVID-19 Impact on the Market
5. Global Gynecology Drugs Market Size and Growth
5.1. Global Gynecology Drugs Market Drivers and Restraints
5.1.1. Drivers of the Market
5.1.2. Restraints of the Market
5.2. Global Gynecology Drugs Historic Market Size and Growth, 2018-2023, Value ($ Billion)
5.3. Global Gynecology Drugs Forecast Market Size and Growth, 2023-2028, 2033F, Value ($ Billion)
6. Gynecology Drugs Market Segmentation
6.1. Global Gynecology Drugs Market, Segmentation by Therapeutics, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Hormonal Therapy
  • Non-Hormonal Therapy
6.2. Global Gynecology Drugs Market, Segmentation by Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Gynecology Cancers
  • Menopausal Disorder
  • Polycystic Ovary Syndrome
  • Contraception
  • Other Indications
6.3. Global Gynecology Drugs Market, Segmentation by Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
7. Gynecology Drugs Market Regional and Country Analysis
7.1. Global Gynecology Drugs Market, Split by Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
7.2. Global Gynecology Drugs Market, Split by Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
8. Asia-Pacific Gynecology Drugs Market
8.1. Asia-Pacific Gynecology Drugs Market Overview
Region Information, Impact of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Gynecology Drugs Market, Segmentation by Therapeutics, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
8.3. Asia-Pacific Gynecology Drugs Market, Segmentation by Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
8.4. Asia-Pacific Gynecology Drugs Market, Segmentation by Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
9. China Gynecology Drugs Market
9.1. China Gynecology Drugs Market Overview
9.2. China Gynecology Drugs Market, Segmentation by Therapeutics, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
9.3. China Gynecology Drugs Market, Segmentation by Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
9.4. China Gynecology Drugs Market, Segmentation by Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
10. India Gynecology Drugs Market
10.1. India Gynecology Drugs Market, Segmentation by Therapeutics, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
10.2. India Gynecology Drugs Market, Segmentation by Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
10.3. India Gynecology Drugs Market, Segmentation by Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
11. Japan Gynecology Drugs Market
11.1. Japan Gynecology Drugs Market Overview
11.2. Japan Gynecology Drugs Market, Segmentation by Therapeutics, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
11.3. Japan Gynecology Drugs Market, Segmentation by Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
11.4. Japan Gynecology Drugs Market, Segmentation by Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
12. Australia Gynecology Drugs Market
12.1. Australia Gynecology Drugs Market, Segmentation by Therapeutics, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
12.2. Australia Gynecology Drugs Market, Segmentation by Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
12.3. Australia Gynecology Drugs Market, Segmentation by Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
13. Indonesia Gynecology Drugs Market
13.1. Indonesia Gynecology Drugs Market, Segmentation by Therapeutics, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
13.2. Indonesia Gynecology Drugs Market, Segmentation by Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
13.3. Indonesia Gynecology Drugs Market, Segmentation by Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
14. South Korea Gynecology Drugs Market
14.1. South Korea Gynecology Drugs Market Overview
14.2. South Korea Gynecology Drugs Market, Segmentation by Therapeutics, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
14.3. South Korea Gynecology Drugs Market, Segmentation by Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
14.4. South Korea Gynecology Drugs Market, Segmentation by Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
15. Western Europe Gynecology Drugs Market
15.1. Western Europe Gynecology Drugs Market Overview
15.2. Western Europe Gynecology Drugs Market, Segmentation by Therapeutics, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
15.3. Western Europe Gynecology Drugs Market, Segmentation by Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
15.4. Western Europe Gynecology Drugs Market, Segmentation by Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
16. UK Gynecology Drugs Market
16.1. UK Gynecology Drugs Market, Segmentation by Therapeutics, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
16.2. UK Gynecology Drugs Market, Segmentation by Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
16.3. UK Gynecology Drugs Market, Segmentation by Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
17. Germany Gynecology Drugs Market
17.1. Germany Gynecology Drugs Market, Segmentation by Therapeutics, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
17.2. Germany Gynecology Drugs Market, Segmentation by Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
17.3. Germany Gynecology Drugs Market, Segmentation by Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
18. France Gynecology Drugs Market
18.1. France Gynecology Drugs Market, Segmentation by Therapeutics, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
18.2. France Gynecology Drugs Market, Segmentation by Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
18.3. France Gynecology Drugs Market, Segmentation by Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
19. Italy Gynecology Drugs Market
19.1. Italy Gynecology Drugs Market, Segmentation by Therapeutics, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
19.2. Italy Gynecology Drugs Market, Segmentation by Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
19.3. Italy Gynecology Drugs Market, Segmentation by Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
20. Spain Gynecology Drugs Market
20.1. Spain Gynecology Drugs Market, Segmentation by Therapeutics, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
20.2. Spain Gynecology Drugs Market, Segmentation by Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
20.3. Spain Gynecology Drugs Market, Segmentation by Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
21. Eastern Europe Gynecology Drugs Market
21.1. Eastern Europe Gynecology Drugs Market Overview
21.2. Eastern Europe Gynecology Drugs Market, Segmentation by Therapeutics, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
21.3. Eastern Europe Gynecology Drugs Market, Segmentation by Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
21.4. Eastern Europe Gynecology Drugs Market, Segmentation by Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
22. Russia Gynecology Drugs Market
22.1. Russia Gynecology Drugs Market, Segmentation by Therapeutics, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
22.2. Russia Gynecology Drugs Market, Segmentation by Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
22.3. Russia Gynecology Drugs Market, Segmentation by Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
23. North America Gynecology Drugs Market
23.1. North America Gynecology Drugs Market Overview
23.2. North America Gynecology Drugs Market, Segmentation by Therapeutics, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
23.3. North America Gynecology Drugs Market, Segmentation by Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
23.4. North America Gynecology Drugs Market, Segmentation by Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
24. USA Gynecology Drugs Market
24.1. USA Gynecology Drugs Market Overview
24.2. USA Gynecology Drugs Market, Segmentation by Therapeutics, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
24.3. USA Gynecology Drugs Market, Segmentation by Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
24.4. USA Gynecology Drugs Market, Segmentation by Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
25. Canada Gynecology Drugs Market
25.1. Canada Gynecology Drugs Market Overview
25.2. Canada Gynecology Drugs Market, Segmentation by Therapeutics, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
25.3. Canada Gynecology Drugs Market, Segmentation by Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
25.4. Canada Gynecology Drugs Market, Segmentation by Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
26. South America Gynecology Drugs Market
26.1. South America Gynecology Drugs Market Overview
26.2. South America Gynecology Drugs Market, Segmentation by Therapeutics, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
26.3. South America Gynecology Drugs Market, Segmentation by Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
26.4. South America Gynecology Drugs Market, Segmentation by Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
27. Brazil Gynecology Drugs Market
27.1. Brazil Gynecology Drugs Market, Segmentation by Therapeutics, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
27.2. Brazil Gynecology Drugs Market, Segmentation by Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
27.3. Brazil Gynecology Drugs Market, Segmentation by Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
28. Middle East Gynecology Drugs Market
28.1. Middle East Gynecology Drugs Market Overview
28.2. Middle East Gynecology Drugs Market, Segmentation by Therapeutics, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
28.3. Middle East Gynecology Drugs Market, Segmentation by Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
28.4. Middle East Gynecology Drugs Market, Segmentation by Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
29. Africa Gynecology Drugs Market
29.1. Africa Gynecology Drugs Market Overview
29.2. Africa Gynecology Drugs Market, Segmentation by Therapeutics, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
29.3. Africa Gynecology Drugs Market, Segmentation by Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
29.4. Africa Gynecology Drugs Market, Segmentation by Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
30. Gynecology Drugs Market Competitive Landscape and Company Profiles
30.1. Gynecology Drugs Market Competitive Landscape
30.2. Gynecology Drugs Market Company Profiles
30.2.1. Merck & Co. Inc.
30.2.1.1. Overview
30.2.1.2. Products and Services
30.2.1.3. Strategy
30.2.1.4. Financial Performance
30.2.2. AbbVie
30.2.2.1. Overview
30.2.2.2. Products and Services
30.2.2.3. Strategy
30.2.2.4. Financial Performance
30.2.3. Hoffmann-La Roche Ltd.
30.2.3.1. Overview
30.2.3.2. Products and Services
30.2.3.3. Strategy
30.2.3.4. Financial Performance
30.2.4. GlaxoSmithKline Plc
30.2.4.1. Overview
30.2.4.2. Products and Services
30.2.4.3. Strategy
30.2.4.4. Financial Performance
30.2.5. Pfizer Inc.
30.2.5.1. Overview
30.2.5.2. Products and Services
30.2.5.3. Strategy
30.2.5.4. Financial Performance
31. Gynecology Drugs Market Other Major and Innovative Companies
31.1. Furukawa Electric
31.2. Motherson Sumi
31.3. LS Cables & Systems
31.4. HUBER+SUHNER.
31.5. Acome
31.6. Yazaki Corporation
31.7. Fujikura Ltd.
31.8. Robert Bosch
31.9. HELLA GmbH & Co. KGaA
31.10. Coroplast Harness Technology Sp. z oo sp. k
31.11. EK Elektrokabel FABRYKA KABLI Karolak i synowie sp. z o.o.
31.12. Coroflex Poland Sp. z o.o Sp. k.
31.13. Eltrim Kable Sp. z o. o
31.14. Anixter
31.15. Allied Wire & Cable Inc
32. Global Gynecology Drugs Market Competitive Benchmarking33. Global Gynecology Drugs Market Competitive Dashboard34. Key Mergers and Acquisitions in the Gynecology Drugs Market
35. Gynecology Drugs Market Future Outlook and Potential Analysis
35.1 Gynecology Drugs Market in 2028 - Countries Offering Most New Opportunities
35.2 Gynecology Drugs Market in 2028 - Segments Offering Most New Opportunities
35.3 Gynecology Drugs Market in 2028 - Growth Strategies
35.3.1 Market Trend-based Strategies
35.3.2 Competitor Strategies
36. Appendix
36.1. Abbreviations
36.2. Currencies
36.3. Historic and Forecast Inflation Rates
36.4. Research Inquiries
36.5. About the Analyst
36.6. Copyright and Disclaimer

Executive Summary

Gynecology Drugs Global Market Report 2024 provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on gynecology drugs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
  • Understand how the market has been affected by the coronavirus and how it is responding as the impact of the virus abates.
  • Assess the Russia-Ukraine war’s impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
  • Measure the impact of high global inflation on market growth.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis.
  • Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for gynecology drugs? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? This report answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include:
  • The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.
  • The impact of higher inflation in many countries and the resulting spike in interest rates.
  • The continued but declining impact of COVID-19 on supply chains and consumption patterns.
  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Report Scope

Markets Covered:
1) By Therapeutics: Hormonal Therapy; Non-Hormonal Therapy
2) By Indication: Gynecology Cancers; Menopausal Disorder; Polycystic Ovary Syndrome; Contraception; Other Indications
3) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies

Key Companies Mentioned: Merck & Co. Inc.; AbbVie; Hoffmann-La Roche Ltd.; GlaxoSmithKline Plc; Pfizer Inc.

Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain

Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa

Time Series: Five years historic and ten years forecast

Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita

Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments

Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes

Delivery Format: PDF, Word and Excel Data Dashboard

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Merck & Co. Inc.
  • AbbVie
  • Hoffmann-La Roche Ltd.
  • GlaxoSmithKline Plc
  • Pfizer Inc.
  • Furukawa Electric
  • Motherson Sumi
  • LS Cables & Systems
  • HUBER+SUHNER.
  • Acome
  • Yazaki Corporation
  • Fujikura Ltd.
  • Robert Bosch
  • HELLA GmbH & Co. KGaA
  • Coroplast Harness Technology Sp. z oo sp. k
  • EK Elektrokabel FABRYKA KABLI Karolak i synowie sp. z o.o.
  • Coroflex Poland Sp. z o.o Sp. k.
  • Eltrim Kable Sp. z o. o
  • Anixter
  • Allied Wire & Cable Inc
  • Emcocables
  • Navcar S.A.S
  • Wirex Cable SA
  • Sistemas de Argentina S.A
  • ARJ Water Technology LLC
  • Fajr Al Hind LLC
  • Haji Commercial Co LLC
  • Bahra Cables
  • Coficab Group

Methodology

Loading
LOADING...

Table Information